Fate Therapeutics Inc. (FATE)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 0 |
| Ownership rank: | -- |
| % of all portfolios: | 0% |
| |
| Total insider Buys/Sells last 6 months: |
| Transactions | Total |
| Buys |
1 |
$668,580 |
| Sells |
4 |
$605,382 |
|
Portfolio Manager |
% of portfolio |
Recent activity |
Shares |
Value |
Open Market Insider Buys
| Date Filed |
Reporting Name |
Relationship |
Trans. Date |
Shares |
Price $ |
Total Value $ |
| 26 Dec 2024 |
REDMILE GROUP, LLC |
Director , 10% |
20 Dec 2024 |
397,964 |
1.68 |
668,580 |
| 28 Dec 2023 |
REDMILE GROUP, LLC |
Director , 10% |
26 Dec 2023 |
44,630 |
3.72 |
166,024 |
| 21 Apr 2023 |
REDMILE GROUP, LLC |
Director , 10% |
21 Apr 2023 |
256,639 |
6.18 |
1,586,029 |
| 21 Apr 2023 |
REDMILE GROUP, LLC |
Director , 10% |
20 Apr 2023 |
20,000 |
5.99 |
119,800 |
| 17 Apr 2023 |
REDMILE GROUP, LLC |
Director , 10% |
14 Apr 2023 |
25,700 |
6.00 |
154,200 |
| 13 Jan 2023 |
MENDLEIN JOHN |
Director |
13 Jan 2023 |
36,631 |
5.43 |
198,906 |
| 13 Jan 2023 |
MENDLEIN JOHN |
Director |
11 Jan 2023 |
88,048 |
5.67 |
499,232 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.
P = Preferred Stock